The expansion of Medicaid eligibility was associated with improved overall survival among patients with resected Merkel cell ...

We unite the leading researchers and cancer specialists of Fred Hutch and UW Medicine so you can take part in Merkel cell carcinoma (MCC) research through clinical trials not available everywhere.

Please provide your email address to receive an email when new articles are posted on . Merkel cell carcinoma is often diagnosed after metastasis to other organs. However, new findings show those with ...

Understanding the stages of Merkel cell carcinoma (MCC) helps you and your physician know how far the cancer has grown or spread. These stages also guide decisions about the treatment options your ...

A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers ...

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the ...

Merkel cell polyomavirus (MCPyV) and ambient ultraviolet radiation (UVR) exposure account for most Merkel cell carcinoma (MCC) cases in the United States. Researchers evaluated 38,020 MCC cases (38% ...

Tailoring treatment to patient risk and disease burden is crucial, especially for those with extensive actinic keratosis or recurrent keratinocyte cancers. Speakers delved into innovative strategies ...

SEATTLE ― The use of Mohs surgery may improve survival for patients with early-stage Merkel cell carcinoma (MCC), results from a large, retrospective study show. As compared with conventional wide ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

IFx-2.0, an innate immune agonist, targets resistance to immune checkpoint inhibitors in advanced cutaneous melanoma, receiving FDA orphan drug designation. Phase 1 trials showed IFx-2.0's safety and ...